TerminatedPhase 3ketamine
Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED
Sponsored by Abigail Nixon
NCT ID
NCT04150757
Target Enrollment
5 participants
Start Date
2019-12-19
Est. Completion
2022-06-01
About This Study
This will be a descriptive cohort study of intranasal ketamine as the initial analgesic for children with sickle cell disease who present to the pediatric emergency department with vaso-occlusive crisis and are awaiting intravenous line placement.
Conditions Studied
Interventions
- •Intranasal ketamine
Eligibility
Age:3 Years - 25 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * History of Hemoglobin SS or SC disease * Age 3 years old to 25 years old presenting to the PED with vaso-occlusive with moderate-severe pain determined at triage as pain score (FACES or numeric rating scale) ≥ 5 * Parent or patient willing to provide consent/assent * English speaking Exclusion Criteria: * Patient with concern for more severe complications including acute chest, splenic sequestration, sepsis, stroke, non-VOC pain, asthma exacerbation * Allergy to ketamine * GCS\<15 * Obstructive nasal anatomy as per parent history * History of a psychiatric disorder * Pregnant patients will be excluded. Female patients \> 12 years old are routinely tested for pregnancy in our PED. Patients found to be pregnant will not be enrolled in study.
Study Locations (2)
Jacobi Medical Center
The Bronx, New York, United States
JACOBI
The Bronx, New York, United States